R. Gerolami et al., Gene transfer to hepatocellular carcinoma: Transduction efficacy and transgene expression kinetics by using retroviral and lentiviral vectors, CANC GENE T, 7(9), 2000, pp. 1286-1292
Gene therapy is an attractive therapy for hepatocarcinoma, and several appr
oaches have been studied using murine leukemia virus-derived retroviruses.
We compared gene transfer efficacy and transgene expression kinetics after
transduction of hepatocarcinoma cell lines using enhanced green fluorescent
protein (EGFP)-expressing murine leukemia virus-derived retroviral vectors
and HIV-derived lentiviral vectors. First, we showed that both retroviral
and lentiviral vectors efficiently transduce cycling hepatocarcinoma cell l
ines in vitro. However. after cell cycle arrest, transduction efficacy rema
ined the same for tentiviral vectors bur it decreased by 80% for retroviral
vectors. Second, we studied EGFP expression kinetics using lentiviral vect
ors expressing EGFP under the control of cytomegalovirus (CMV) or phosphogl
ycerolkinase (PGK) promoter. We show that the CMV promoter allows a stronge
r EGFP expression than the PGK promoter. However, in contrast to PGK-driven
EGFP expression, which persists up to 2 months after transduction. CMV-dri
ven EGFP expression rapidly decreased with time. This phenomenon is due to
promoter silencing, and EGFP expression can be restored in transduced cells
by using transcription activators such as interleukin-6 or phorbol myrista
te actate/ionomycin and, to a lesser extent, the demethylating agent 5'-aza
cytidine. Altogether, our results suggest that lentiviral vectors. which al
low efficient transduction of hepatocarcinoma cell lines with a strong and
a sustained expression according to the promoter used, are promising tools
for gene therapy of hepatocarcinomas.